×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Loan Against Mutual Fund
Apply Now
Gold Loan
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Eco Pulse
MC Learn
Elections 2026
Seasonality Analysis
Big Shark Portfolios
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Global Wealth Summit
Unlocking opportunities in Metal and Mining
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
IPL 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Cdmo
Cdmo
Syngene: How should one position for it after a disappointing quarter?
Divi’s Lab: Getting ready for peptide opportunity
Navin Fluorine: Revenue visibility getting clearer for the CDMO business
Acutaas Chemicals: Next fiscal to see traction in new businesses
Sai Life Sciences: Getting positioned for complex offerings
Divi’s Lab: Time to take some profit off the table?
Laurus Labs: Is the healthy growth already priced in?
Divi's Labs, Laurus Labs, other pharma shares rise up to 5% as US Senate passes Biosecure Act
What does the new US tariff salvo mean for Indian pharma?
Laurus Labs: Is it time to book profit?
Syngene: How soon can it overcome near-term worries?
How to navigate markets amid Fed’s pause and stagflation risks
Generics drugs are a shrinking market, CDMO hasn’t delivered, hospitals and diagnostics better plays for investors
Divi’s Lab: Capex cycle picks up to meet emerging CDMO demand
What does Trump’s MFN clause mean for the Indian pharma landscape?
Trump’s drug pricing regulation: How does it impact Indian pharma?
Ami Organics: Internal accruals fuel growth capex
Laurus Labs: CDMO-led growth to enhance return ratios
Syngene: Conversion of pilot projects to long-term contracts a big positive
Ami Organics | Strong growth runway for the CDMO business? | Stock of the Day
Ami Organics: CDMO business brightens growth outlook
Akums Drugs signs Rs 1,760 crore CDMO pact with a pharma major for European supply
Divis Lab: GLP-1 opportunity to unfold in the medium term
Senores IPO: A B2B play in pharma generics
Piramal Pharma shares surge 5% after JM Financial recommends Buy, sees 15% topline growth over FY24-27
View More
Home
Markets
Loans
Gold Loan
News
Portfolio